bioavailability of glp-1 treatments If weight loss is part your resolution, understanding your options matters. medications are available in both injectable and oral forms. Injectable and oral GLP-1 differ in frequency, absorption, and A Pharmacological and Clinical Overview

There are small human studies

48 In the Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) trial in adult participants with obesity but without T2DM, tirzepatide (10 mg or 15 mg) achieved greater weight loss compared with semaglutide (1.7 mg or 2.4 mg weekly dose): 20.2% (95% CI 21.4 to 19.1) versus -13.7% (95% CI 14.9 to 12.6) at week 72

JCI Insight 8 , e170671 (2023)

Achieved dose-dependent weight reductions, with lower doses producing steady, moderate loss Experienced consistent weight improvements whether they had obesity alone or obesity with type 2 diabetes This level of weight loss is similar to early GLP-1 injection trials but delivered through a once-daily pill